Who are Hib Vaccine Group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hib conjugate vaccine, Hib (Hiberix™), Hiberix™ Vaccine, Minhai-HIB, CombAct-HIB®, LBVH0101 (Hib vaccine).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hib-vaccine-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hib Vaccine Group — Competitive Intelligence Brief

Hib Vaccine Group (Hib Vaccine Group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

phase 3 vaccine Haemophilus influenzae type b polysaccharide capsule Immunology Biologic Live · refreshed every 30 min

Target snapshot

Hib Vaccine Group (Hib Vaccine Group) — Beijing Minhai Biotechnology Co., Ltd. Hib vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) bacteria, preventing infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hib Vaccine Group TARGET	Hib Vaccine Group	Beijing Minhai Biotechnology Co., Ltd	phase 3	vaccine	Haemophilus influenzae type b polysaccharide capsule
Hib conjugate vaccine	Hib conjugate vaccine	Public Health England	marketed	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule
Hib (Hiberix™)	Hib (Hiberix™)	GlaxoSmithKline	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule (PRP)
Hiberix™ Vaccine	Hiberix™ Vaccine	LG Life Sciences	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule (PRP)
Minhai-HIB	Minhai-HIB	Beijing Minhai Biotechnology Co., Ltd	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule
CombAct-HIB®	CombAct-HIB®	Sanofi Pasteur, a Sanofi Company	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule
LBVH0101 (Hib vaccine)	LBVH0101 (Hib vaccine)	LG Life Sciences	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule (PRP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hib Vaccine Group — Competitive Intelligence Brief. https://druglandscape.com/ci/hib-vaccine-group. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab